Dose debate: which rituximab regimen works best for rare blistering disease?
NCT ID NCT07457944
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked back at 275 pemphigus patients to see how different doses of rituximab affected disease control and relapse. Pemphigus is a rare autoimmune disease that causes painful blisters on skin and mucous membranes. Researchers tracked outcomes like flare-ups, side effects, and steroid use to find the safest and most effective dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab
What this could lead to
If successful, this study could help doctors choose the best rituximab dose to control pemphigus with fewer side effects.
What could go wrong
This is a retrospective study, not a controlled trial, so results may be less reliable. Rituximab can cause serious infections or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEMPHIGUS VULGARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China